

May 17, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Outcome of Board Meeting held on May 17, 2019

Ref: Compliances under SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 (“Listing Regulations”)

Dear Sir/Madam,

Please take note that the Board of Directors in their meeting held today i.e. May 17, 2019 approved following matters:

1. The Audited Standalone and Consolidated Financial Results (“Results”) of the Company for the Quarter and Financial Year ended March 31, 2019. A copy of the signed Results along with Auditors Report and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached herewith.
2. Convening of 25th Annual General Meeting (AGM) of the Company on Monday, August 12, 2019.
3. Recommendation of final dividend of Rs. 3.5/- per equity share (@ 35 % on a face value of Rs. 10/- per share) for the year ended March 31, 2019. The dividend, if approved by the shareholders at the ensuing Annual General Meeting (AGM) will be paid on or after August 21, 2019.
4. Pursuant to Regulation 42 of Listing Regulations, the Register of Members and Share Transfer books of the Company will remain closed from Tuesday, August 6, 2019 to Monday, August 12, 2019 (both days inclusive) for the purpose of 25th AGM and payment of dividend (if approved by the Shareholders).

Symbol	Type of security	Book Closure both days inclusive	Record Date	Purpose
NSE - LALPATHLAB BSE – 539524	Equity	Tuesday, August 6, 2019 To Monday, August 12, 2019	Not Applicable	1. 25 th Annual General Meeting (AGM) 2. Payment of dividend, if approved at the ensuing Annual General Meeting



5. The cut-off date for the purpose of payment of dividend and voting at the ensuing Annual General Meeting will be Monday, August 5, 2019.
6. Based on the recommendations of the Nomination and Remuneration Committee and subject to the approval of shareholders at the ensuing AGM, the Board of Directors appointed Dr. Archana Lal Erdmann as an Additional Director (Non-Executive), liable to retire by rotation, on the Board of the Company w.e.f. May 17, 2019.
Details as required under SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 are attached herewith as Annexure A.
7. In line with good Corporate Governance Practices, Mr. Sunil Varma, Independent Director and Chairman of the Audit Committee of the Company has also been designated as Lead Independent Director w.e.f May 17, 2019.
8. The Board Meeting commenced at 11 A.M. and concluded at 2:38 P.M.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited



Rajat Kalra
Company Secretary and Legal Head



Encl: As above

Annexure – A

Reason for change	Appointment
Date of appointment	May 17, 2019
Brief Profile	<p>Archana Lal Erdmann holds an MBBS degree (Bachelor of Medicine and Bachelor of Surgery) from Bharati Vidyapeeth Medical College, Pune and completed M.D. & DNB (Pathology) from Sri Ramachandra University, Chennai, Tamil Nadu. Dr. Archana is an American board certified Geneticist, and completed fellowships in Clinical Cytogenetics and Clinical Molecular Genetics from Stanford University School of Medicine, California, USA.</p> <p>Dr. Archana brings 10 years of experience in laboratory genetics and genomics testing with a focus on research for genetic tests for both inherited and acquired genetic diseases, developing next generation sequencing-based tests for genotyping tumors, clinical variant curation, and expanding the scope of genetic testing with the goal of identifying patients eligible for novel targeting therapies.</p>
Disclosure of relationships between directors	Dr. Archana Lal Erdmann is daughter of (Hony) Brig. Dr. Arvind Lal and Dr. Vandana Lal, Promoter Directors of the Company

Note - Dr. Archana Lal Erdmann is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other authority



May 17, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015, we hereby confirm that the Audit Report issued by M/s Deloitte Haskins & Sells LLP, Statutory Auditors of the Company on the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2019 is with Unmodified Opinion.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra

Company Secretary and Legal Head



INDEPENDENT AUDITORS' REPORT

TO THE BOARD OF DIRECTORS OF DR. LAL PATHLABS LIMITED

1. We have audited the accompanying Statement of Consolidated Financial Results of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the year ended 31 March, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Parent's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 5 below, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements and the other financial information of subsidiaries referred to in paragraph 5 below, the Statement:
 - a. includes the results of the entities listed in Annexure A.
 - b. is presented in accordance with the requirements of Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016; and
 - c. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, Total comprehensive income and other financial information of the Group for the year ended 31 March, 2019.




5. We did not audit the financial statements / financial information of four subsidiaries included in the consolidated financial results, whose financial statements / financial information reflect total assets of INR 105 million as at 31 March, 2019, total revenues of INR 111 million, total net loss after tax of INR 4 million and total comprehensive loss of INR 4 million for the year ended on that date, as considered in the consolidated financial results. These financial statements / financial information have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

6. The Statement includes the results for the Quarter ended 31 March, 2019 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)




Jitendra Agarwal
Partner
(Membership No. 87104)

Place: Delhi
Date: 17 May, 2019

Statement of Consolidated Audited Financial Results for the quarter and year ended 31 March, 2019
(Rs. in million except as stated)

Particulars	3 months ended 31 March, 2019	Preceding 3 months ended 31 December, 2018	Corresponding 3 months ended 31 March, 2018	Year ended 31 March, 2019	Previous year ended 31 March, 2018
	(See note iv) (Unaudited)	(Unaudited)	(See note iv and v) (Unaudited)	(See note iv) (Audited)	(See note iv and v) (Audited)
1 (a) Revenue from operations	3,011	2,925	2,668	12,034	10,569
(b) Other income	135	122	89	460	312
Total income	3,146	3,047	2,757	12,494	10,881
2 Expenses					
(a) Cost of materials consumed	652	653	575	2,624	2,260
(b) Employee benefits expense	568	519	466	2,083	1,807
(c) Finance costs	1	3	2	8	8
(d) Depreciation and amortisation expense	104	96	107	382	331
(e) Fees to collection centers/channel partners	371	374	330	1,509	1,276
(f) Other expenses	758	723	657	2,882	2,586
Total expenses	2,454	2,368	2,137	9,488	8,268
3 Profit before tax	692	679	620	3,006	2,613
4 Tax expense					
(a) Current tax	211	220	202	1,036	930
(b) Deferred tax	7	(2)	17	(35)	(34)
Total tax expense	218	218	219	1,001	896
5 Profit for the period (A)	474	461	401	2,005	1,717
6 Other comprehensive income					
-Items that will not be reclassified to profit or loss Remeasurement of the defined benefit plans	(34)	2	1	(30)	6
-Income tax in relation to the items that will not be reclassified to profit or loss	11	-	-	10	(2)
-Items that may be reclassified to profit or loss Exchange differences on translation of foreign operations	-	(1)	-	-	-
-Income tax in relation to the items that will be reclassified to profit or loss	-	-	-	-	-
Total other comprehensive income (B)	(23)	1	1	(20)	4
7 Total comprehensive income (A+B)	451	462	402	1,985	1,721
Profit for the period attributable to:					
Owners of the Company	471	458	401	1,992	1,707
Non Controlling Interest	3	3	1	13	10
	474	461	402	2,005	1,717
Other comprehensive income for the period attributable to:					
Owners of the Company	(23)	1	1	(20)	4
Non Controlling Interest	-	-	-	-	-
	(23)	1	1	(20)	4
Total comprehensive income for the period attributable to:					
Owners of the Company	448	459	402	1,972	1,711
Non Controlling Interest	3	3	1	13	10
	451	462	403	1,985	1,721
8 Paid-up equity share capital (Face Value of Rs. 10 per share)	833	833	833	833	833
9 Other equity				8,622	7,045
10 Earnings per share (Rs.) (not annualised)					
-Basic	5.72	5.56	4.88	24.19	20.85
-Diluted	5.71	5.55	4.87	24.15	20.82

Dr. Lal PathLabs Limited

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 17 May, 2019.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').
- iii. These financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI circular dated 5 July, 2016 and other accounting principles generally accepted in India.
- iv. Figures for the quarter ended 31 March, 2019 and 31 March, 2018 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter of the year ended 31 March, 2019 and 31 March, 2018 respectively.
- v. The Hon'ble New Delhi Bench and Hon'ble Ahmedabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') sanctioned the Scheme of Amalgamation between the Parent Company (Transferee Company) and its wholly owned subsidiary (Transferor Company) by the name Delta Ria and Pathology Private Limited on October 23, 2018 and December 11, 2018 respectively.

The appointed date as per scheme is 1 April, 2017. The Scheme envisages transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company

Pursuant to the Scheme becoming effective, the amalgamation has been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company have been accounted for at their book value, in the books of Transferee Company.

Accordingly, the results for the quarter and year ended 31 March, 2018 have been restated to give effect of the amalgamation. Consequent to this restatement, profit after tax for the quarter and year ended 31 March 2018 is lower by INR 1 million and INR 1 million respectively.
- vi. During the year ended 31 March, 2019, the Parent Company has issued 8,866 equity shares of face value of Rs. 10 each to the employees on exercise of employee stock options.
- vii. Effective 1 April, 2018, Ind AS 115 "Revenue from Contracts with Customers" has been adopted by the Group using the cumulative catch-up transition method applied to contracts that were not completed as of 31 March, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The adoption of Ind AS 115 did not have any material impact on the consolidated results for the quarter and year ended 31 March, 2019.
- viii. During the year ended 31 March, 2018, the Parent Company had acquired 70% equity stake in Dr. Lal Pathlabs Bangladesh Pvt. Ltd., Bangladesh for a total consideration of Rs 18.09 million. During the year ended 31 March, 2019, the Parent Company has made a further investment of Rs 24.58 million in Dr. Lal PathLabs Bangladesh Pvt. Ltd. through subscription of additional shares.
- ix. During the current year, two wholly owned subsidiaries of the Parent Company, Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited have been incorporated in India. The Parent Company has subscribed to equity share capital amounting to INR 1.00 million in each of these subsidiaries.
- x. Subsequent to the year end, 'Pathlabs Unifiers Private Limited' (a subsidiary) has purchased the business of "Bawankar Pathology" engaged in the business of providing pathological diagnostics services in Bhandara, on a going concern basis for a purchase consideration of INR 52.00 million.
- xi. The Board of Directors of the Parent company had approved an interim dividend of Rs. 2.50 per equity share (face value of Rs. 10 each) at their meeting held on 6 November, 2018 which was subsequently paid in the current year.
- xii. The Parent Company has proposed a final dividend of 35% (Rs. 3.50 per equity share having face value of Rs. 10) for the financial year ended 2018-19. The total dividend for the year including the final dividend (Subject to approval of shareholders at the ensuing Annual General meeting) is Rs. 6.00 per equity share having face value of Rs. 10 each.
- xiii. The Board of Directors, which has been identified as being the chief operating decision maker (CCDM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segment Reporting', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- xiv. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities.

Place: New Delhi
Date: 17 May, 2019

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited

(Hon'ble) **Brig. Dr. Arvind Lal**
Chairman and Managing Director

Dr. Lal PathLabs Limited
Statement of Consolidated Assets and Liabilities
(Rs. in millions except as stated)

Particulars	As at 31 March, 2019 (Audited)	As at 31 March, 2018 (Audited)
Assets		
1 Non-current assets		
(a) Property, plant and equipment	1,601	1,598
(b) Capital work-in-progress	34	96
(c) Goodwill	280	279
(d) Other intangible assets	206	198
(e) Financial assets		
(i) Loans	-	1
(ii) Other financial assets	203	379
(f) Non-current tax assets (net)	133	93
(g) Deferred tax assets (net)	215	169
(h) Other non-current assets	97	113
Total non-current assets	2,769	2,926
2. Current assets		
(a) Inventories	285	273
(b) Financial assets		
(i) Investments	1,848	1,448
(ii) Trade receivables	532	412
(iii) Cash and cash equivalents	1,294	658
(iv) Bank balances other than (iii) above	3,609	2,477
(v) Loans	9	2
(vi) Other financial assets	463	799
(c) Other current assets	96	161
Total current assets	8,136	6,230
Total assets	10,905	9,156
Equity and Liabilities		
1. Equity		
(a) Equity share capital	833	833
(b) Other equity	8,622	7,045
Equity attributable to the owners of the Company	9,455	7,878
Non controlling interest	55	38
Total equity	9,510	7,916
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Other financial liabilities	12	76
(b) Other non-current liabilities	-	4
Total non-current liabilities	12	80
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
Total outstanding dues of micro enterprises and small enterprises; and	22	1
Total outstanding dues of creditors other than micro enterprises and small enterprises	776	654
sub-total	798	655
(ii) Other financial liabilities	291	270
(b) Provisions	134	87
(c) Current tax liabilities (net)	45	14
(d) Other current liabilities	115	134
Total current liabilities	1,383	1,160
Total liabilities	1,395	1,240
Total equity and liabilities	10,905	9,156

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF DR. LAL PATHLABS LIMITED

1. We have audited the accompanying Statement of Standalone Financial Results of **Dr. Lal PathLabs Limited** ("the Company"), for the year ended 31 March, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
 - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended 31 March, 2019.



**Deloitte
Haskins & Sells LLP**

5. The Statement includes the results for the Quarter ended 31 March, 2019 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in black ink, appearing to read "Jitendra Agarwal".

Jitendra Agarwal
Partner
(Membership No. 87104)

Place: 17 May, 2019
Date: Delhi

Statement of Standalone Audited Financial Results for the quarter and year ended 31 March, 2019

(Rs. in million except as stated)

	Particulars	3 months ended 31 March, 2019	Preceding 3 months ended 31 December, 2018	Corresponding 3 months ended 31 March, 2018	Year ended 31 March, 2019	Previous year ended 31 March, 2018
		(See note iii)		(See note iii and iv)	(See note iii)	(See note iii and iv)
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	(a) Revenue from operations	2,920	2,828	2,585	11,649	10,240
	(b) Other income	130	119	87	465	315
	Total income	3,050	2,947	2,672	12,114	10,555
2	Expenses					
	(a) Cost of materials consumed	633	635	557	2,550	2,193
	(b) Employee benefits expense	552	501	448	2,019	1,751
	(c) Finance costs	1	2	2	7	8
	(d) Depreciation and amortisation expense	99	90	99	362	310
	(e) Fees to collection centers/channel partners	366	367	325	1,483	1,271
	(f) Other expenses	728	699	627	2,770	2,465
	Total expenses	2,379	2,294	2,058	9,191	7,998
3	Profit before tax	671	653	614	2,923	2,557
4	Tax expense					
	(a) Current tax	207	211	199	1,005	909
	(b) Deferred tax	4	(1)	18	(36)	(34)
	Total tax expense	211	210	217	969	875
5	Profit for the period (A)	460	443	397	1,954	1,682
6	Other comprehensive income					
	-Items that will not be reclassified to profit or loss Remeasurement of the defined benefit plan	(34)	1	-	(30)	5
	-Income tax in relation to the items that will not be reclassified to profit or loss	12	-	-	11	(2)
	Total other comprehensive income (B)	(22)	1	-	(19)	3
7	Total comprehensive income (A+B)	438	444	397	1,935	1,685
8	Paid-up equity share capital (Face Value of Rs. 10 per share)	833	833	833	833	833
9	Other equity				8,475	6,932
10	Earnings per share (Rs.) (not annualised)					
	- Basic	5.59	5.38	4.83	23.74	20.54
	- Diluted	5.58	5.37	4.82	23.69	20.52

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 17 May, 2019.
- ii. These financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI circular dated 5 July, 2016 and other accounting principles generally accepted in India.
- iii. Figures for the quarter ended 31 March, 2019 and 31 March, 2018 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter of the year ended 31 March, 2019 and 31 March, 2018 respectively.
- iv. The Hon'ble New Delhi Bench and Hon'ble Ahmedabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') sanctioned the Scheme of Amalgamation between the Company (Transferee Company) and its wholly owned subsidiary (Transferor Company) by the name Delta Ria and Pathology Private Limited on October 23, 2018 and December 11, 2018 respectively.


The appointed date as per scheme is 1 April, 2017. The Scheme envisages transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company.

Pursuant to the Scheme becoming effective, the amalgamation has been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company have been accounted for at their book value, in the books of Transferee Company.

Accordingly, the results for the quarter and year ended 31 March, 2018 have been restated to give effect of the amalgamation. Consequent to this restatement, the impact on profit after tax for the quarter ended 31 March 2018 is INR Nil and profit after tax for the year ended 31 March, 2018 is higher by INR 2 million.

- v. During the year ended 31 March, 2019, the Company has issued 8,866 equity shares of face value of Rs. 10 each to the employees on exercise of employee stock options.
- vi. Effective 1 April, 2018, Ind AS 115 "Revenue from Contracts with Customers" has been adopted by the Company using the cumulative catch-up transition method applied to contracts that were not completed as of 31 March, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The adoption of Ind AS 115 did not have any material impact on the results for the quarter and year ended 31 March, 2019.
- vii. During the year ended 31 March, 2018, the Company had acquired 70% equity stake in Dr. Lal Pathlabs Bangladesh Pvt. Ltd., Bangladesh for a total consideration of Rs 18.09 million. During the year ended 31 March, 2019, the Company has made a further investment of Rs 24.58 million in Dr. Lal PathLabs Bangladesh Pvt. Ltd. through subscription of additional shares.
- viii. During the current year, two wholly owned subsidiaries, Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited have been incorporated in India. The Company has subscribed to equity share capital amounting to INR 1.00 million in each of these subsidiaries.
- ix. The Board of Directors of the Company had approved an interim dividend of Rs. 2.50 per equity share (having face value of Rs. 10 each) at their meeting held on 6 November, 2018 which was subsequently paid in the current year.
- x. The Board of Directors of the Company has proposed a final dividend of 35% (Rs. 3.50 per equity share having face value of Rs. 10 each) for the financial year ended 2018-2019. The total dividend for the year including the final dividend (Subject to approval of shareholders at the ensuing Annual General meeting) is Rs. 6.00 per equity share having face value of Rs. 10 each.
- xi. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segment Reporting', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- xii. Refer Annexure A for Statement of standalone Assets and Liabilities.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'g) Brig. Dr. Arvind Lal
Chairman and Managing Director

Place: New Delhi
Date: 17 May, 2019

Dr. Lal PathLabs Limited		
Statement of Standalone Assets and Liabilities		
(Rs. in millions except as stated)		
Particulars	As at 31 March, 2019	As at 31 March, 2018
	(Audited)	(Audited)
Assets		
1. Non-current assets		
(a) Property, plant and equipment	1,513	1,516
(b) Capital work-in-progress	29	94
(c) Goodwill	11	11
(d) Other intangible assets	205	198
(e) Financial assets		
(i) Investments	324	297
(ii) Loans	-	1
(iii) Other financial assets	187	358
(f) Non-current tax assets (net)	126	76
(g) Deferred tax assets (net)	211	164
(h) Other non-current assets	97	113
Total non-current assets	2,703	2,828
2. Current assets		
(a) Inventories	278	267
(b) Financial assets		
(i) Investments	1,817	1,439
(ii) Trade receivables	531	402
(iii) Cash and cash equivalents	1,239	625
(iv) Bank balances other than (iii) above	3,542	2,443
(v) Loans	9	2
(vi) Other financial assets	451	790
(c) Other current assets	95	160
Total current assets	7,962	6,128
Total assets	10,665	8,956
Equity and Liabilities		
1. Equity		
(a) Equity share capital	833	833
(b) Other equity	8,475	6,932
Total equity	9,308	7,765
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Other financial liabilities	12	76
(b) Other non-current liabilities	-	4
Total non-current liabilities	12	80
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
Total outstanding dues of micro enterprises and small enterprises; and	22	1
Total outstanding dues of creditors other than micro enterprises and small enterprises;	750	623
Sub-total	772	624
(ii) Other financial liabilities	285	257
(b) Provisions	131	84
(c) Current tax liabilities (net)	45	14
(d) Other current liabilities	112	132
Total current liabilities	1,345	1,111
Total liabilities	1,357	1,191
Total equity and liabilities	10,665	8,956